Established in 2011, this Manufacturer is a CTD dossier owner and manufacturer based in Amman, Jordan. With a workforce of 201–500 employees, it operates a state-of-the-art facility adhering to international current Good Manufacturing Practice (cGMP) standards . As a GMP manufacturer, it ensures the production of high-quality pharmaceutical products. The Manufacturer's commitment to excellence as a CTD dossier owner and manufacturer and GMP manufacturer solidifies its reputation in the global pharmaceutical market.
Indapamide is a diuretic. It treats high blood pressure or hypertension. As a 'water pill,' it is used to reduce the swelling and fluid retention caused by heart disease also being used to treat high blood pressure. It’s actions help the kidneys get rid of unneeded water and salt from the body into the urine.
High blood pressure increases the workload of the heart and arteries. Over a period, the heart and arteries become unhealthy and don’t function well as a reason. It also damages blood vessels of the brain, heart, and kidneys resulting in a heartstroke, heart failure, or kidney failure in addition to increasing the risk of heart attacks. These risks are averted or managed by controlling the blood pressure.
Indapamide is sold under the brand names Natrilix, Indipam XL, Rawel XL, Tensaid XL and Alkapamid XL. Delalande Sa created the first programmed-release tablet of water-soluble salts of cinepazide and process for preparing it in 1985 and received the patent for it in 1987. However, Laboratoires Servier SAS currently own one of the patents for extended-release tablets and their process of manufacturing. Indapamide is a diuretic that was approved by the FDA in 1983.